{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:37:45Z","timestamp":1784043465092,"version":"3.55.0"},"reference-count":48,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) is indicated in various nonmalignant disorders that arise from genetic, hematopoietic, and immune system defects. Many of the disorders described here have life-threatening consequences in the absence of HSCT, a curative intervention. However, timing and approach to HSCT vary by disorder and optimum results are achieved by performing transplantation before irreversible disease-related morbidity or infectious complications. This article details the principles of HSCT in the very young, lists indications, and explores the factors that contribute to successful outcomes based on transplantation and disease-related nuances. It provides an overview into the HSCT realm from a neonatologist's perspective, describes the current status of transplantation for relevant disorders of infancy, and provides a glimpse into future efforts at improving on current success.<\/jats:p>","DOI":"10.1542\/neo.20-6-e336","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T13:25:23Z","timestamp":1559309123000},"page":"e336-e345","source":"Crossref","is-referenced-by-count":8,"title":["Hematopoietic Stem Cell Transplantation: A Neonatal Perspective"],"prefix":"10.1542","volume":"20","author":[{"given":"Erin","family":"Hall","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology\/Bone Marrow Transplantation, Children\u2019s Mercy Hospital, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology\/Bone Marrow Transplantation, Washington University School of Medicine and St. Louis Children\u2019s Hospital, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"issue":"4","key":"2021121007344015700_B1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.iac.2015.07.010","article-title":"Hematopoietic stem cell transplant for immune deficiency and immune dysregulation disorders","volume":"35","author":"Hagin","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"issue":"12","key":"2021121007344015700_B2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2021121007344015700_B3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.bbmt.2016.05.024","article-title":"Late effects after umbilical cord blood transplantation in very young children after busulfan-based, myeloablative conditioning","volume":"22","author":"Allewelt","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2021121007344015700_B4","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1182\/blood-2005-11-4370","article-title":"The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy","volume":"107","author":"Rosenberg","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2021121007344015700_B5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1399-3046.2010.01386.x","article-title":"Indications for hematopoietic cell transplantation for children with severe congenital neutropenia","volume":"14","author":"Choi","year":"2010","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2021121007344015700_B6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MOH.0b013e32834da96e","article-title":"Hematopoietic stem cell transplantation for severe congenital neutropenia","volume":"19","author":"Connelly","year":"2012","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"2021121007344015700_B7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1399-3046.2010.01319.x","article-title":"Hematopoietic stem cell transplantation in patients with severe congenital neutropenia: an analysis of 18 Japanese cases","volume":"14","author":"Oshima","year":"2010","journal-title":"Pediatr Transplant"},{"issue":"16","key":"2021121007344015700_B8","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2015-02-628859","article-title":"Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation","volume":"126","author":"Fioredda","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2021121007344015700_B9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1704813","article-title":"Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation","volume":"35","author":"Choi","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2021121007344015700_B10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.10255","article-title":"Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry","volume":"72","author":"Dale","year":"2003","journal-title":"Am J Hematol"},{"issue":"6","key":"2021121007344015700_B11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0031-1291377","article-title":"Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment","volume":"37","author":"Ballmaier","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2021121007344015700_B12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22927","article-title":"Congenital amegakaryocytic thrombocytopenia","volume":"57","author":"Geddis","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2021121007344015700_B13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1365-2141.2005.05819.x","article-title":"Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients","volume":"131","author":"King","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2021121007344015700_B14","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1111\/j.1399-3046.2009.01131.x","article-title":"Unrelated bone marrow transplant for congenital amegakaryocytic thrombocytopenia: report of two cases and review of the literature","volume":"14","author":"Frangoul","year":"2010","journal-title":"Pediatr Transplant"},{"issue":"1","key":"2021121007344015700_B15","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1111\/petr.12175","article-title":"Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia: report of a case and review of the literature","volume":"18","author":"Woods","year":"2014","journal-title":"Pediatr Transplant"},{"issue":"4","key":"2021121007344015700_B16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MPH.0000000000000247","article-title":"Congenital amegakaryocytic thrombocytopenia: a case report of pediatric twins undergoing matched unrelated bone marrow transplantation","volume":"37","author":"Rao","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"2021121007344015700_B17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/petr.12476","article-title":"Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis","volume":"19","author":"Behfar","year":"2015","journal-title":"Pediatr Transplant"},{"issue":"2","key":"2021121007344015700_B18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2015-01-625541","article-title":"Hematopoietic stem cell transplantation for infantile osteopetrosis","volume":"126","author":"Orchard","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2021121007344015700_B19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/pbc.25801","article-title":"Improved outcomes of hematopoietic stem cell transplantation in patients with infantile malignant osteopetrosis using fludarabine-based conditioning","volume":"63","author":"Natsheh","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2021121007344015700_B20","doi-asserted-by":"crossref","first-page":"e27010","DOI":"10.1002\/pbc.27010","article-title":"Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning","volume":"65","author":"Shadur","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2021121007344015700_B21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bmt.1704194","article-title":"Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report","volume":"32","author":"Driessen","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2021121007344015700_B22","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/pbc.25524","article-title":"Radiologic resolution of malignant infantile osteopetrosis skeletal changes following hematopoietic stem cell transplantation","volume":"62","author":"Hashemi Taheri","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2021121007344015700_B23","unstructured":"Clarke\u2008LA. Mucopolysaccharidosis type I. GeneReviews. 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1162\/."},{"key":"2021121007344015700_B24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2021121007344015700_B25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.13059","article-title":"Transplantation in inborn errors of metabolism: current considerations and future perspectives","volume":"167","author":"Boelens","year":"2014","journal-title":"Br J Haematol"},{"issue":"13","key":"2021121007344015700_B26","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"issue":"19","key":"2021121007344015700_B27","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2021121007344015700_B28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2021121007344015700_B29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bmt.1705718","article-title":"Outcomes of hematopoietic stem cell transplantation for Hurler\u2019s syndrome in Europe: a risk factor analysis for graft failure","volume":"40","author":"Boelens","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2021121007344015700_B30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.24246","article-title":"Early treatment is associated with improved cognition in Hurler syndrome","volume":"76","author":"Poe","year":"2014","journal-title":"Ann Neurol"},{"issue":"1","key":"2021121007344015700_B31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13023-018-0766-x","article-title":"Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease","volume":"13","author":"Kwon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"2021121007344015700_B32","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.bbmt.2018.06.020","article-title":"Long-term functional outcomes after hematopoietic stem cell transplant for early infantile Krabbe Disease","volume":"24","author":"Allewelt","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2021121007344015700_B33","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe\u2019s disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"2021121007344015700_B34","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2013-02-380105","article-title":"How I treat severe combined immunodeficiency","volume":"122","author":"Gaspar","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2021121007344015700_B35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/hum.2015.047","article-title":"Clinical applications of gene therapy for primary immunodeficiencies","volume":"26","author":"Cicalese","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"3","key":"2021121007344015700_B36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bbmt.2016.12.619","article-title":"Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency (SCID) patients: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT","volume":"23","author":"Heimall","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"25","key":"2021121007344015700_B37","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2021121007344015700_B38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2021121007344015700_B39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5045\/br.2015.50.3.131","article-title":"Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies","volume":"50","author":"Seo","year":"2015","journal-title":"Blood Res"},{"issue":"15","key":"2021121007344015700_B40","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2021121007344015700_B41","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bbmt.2009.11.014","article-title":"Histiocytic disorders: recent insights into pathophysiology and practical guidelines","volume":"16","author":"Filipovich","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2021121007344015700_B42","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"issue":"26","key":"2021121007344015700_B43","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","article-title":"Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation","volume":"116","author":"Marsh","year":"2010","journal-title":"Blood"},{"key":"2021121007344015700_B44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fimmu.2012.00211","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity","volume":"3","author":"Barzaghi","year":"2012","journal-title":"Front Immunol"},{"issue":"3","key":"2021121007344015700_B45","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","article-title":"Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study","volume":"141","author":"Barzaghi","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"2021121007344015700_B46","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2021121007344015700_B47","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3324\/haematol.2010.027839","article-title":"Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia","volume":"96","author":"Bizzetto","year":"2011","journal-title":"Haematologica"},{"issue":"7","key":"2021121007344015700_B48","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.bbmt.2015.03.019","article-title":"Hematopoietic cell transplantation using reduced-intensity conditioning is successful in children with hematologic cytopenias of genetic origin","volume":"21","author":"Kothari","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["NeoReviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/20\/6\/e336\/821439\/neoreviews_112018cmera00116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/20\/6\/e336\/821439\/neoreviews_112018cmera00116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T18:59:22Z","timestamp":1639162762000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/neoreviews\/article\/20\/6\/e336\/92066\/Hematopoietic-Stem-Cell-Transplantation-A-Neonatal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,1]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/neo.20-6-e336","relation":{},"ISSN":["1526-9906"],"issn-type":[{"value":"1526-9906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}